Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isabel Study
2020-004513-13Phase 2Active
- Sponsor
- EMN Research Italy
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in multiple myeloma (MM), sponsored by EMN Research Italy. Primary endpoint: MRD negativity rate. Started Oct 2021; status: active.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-004513-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004513-13.